“Exosome Diagnostics Launches Evidence Development Study for Prostate Cancer Test,” | Bio-Techne Exosome

Skip to main content

Top navigation

GSA Award
For Veterans
HCP Portal
Pay My Bill Online
Contact Us
+1 844 396 7663

Search

Main navigation

Physicians
Patients
Pharma Services
Our Technology
News & Resources
- Literature
- Press
- Webinars
- Events
- Newsletters

Top navigation

GSA Award
For Veterans
HCP Portal
Pay My Bill Online
Contact Us
+1 844 396 7663

Search

“Exosome Diagnostics Launches Evidence Development Study for Prostate Cancer Test,”

News Sep 19, 2017

GenomeWeb

Read full story

(844) 396-7663
exosomedx.info@bio-techne.com
266 Second Ave, Suite 200
Waltham, MA 02451

Footer menu

About Bio-Techne
Management Team
Careers
Investors
Corporate Responsibility
Accreditation and Licensure

Social navigation

Facebook
Twitter
LinkedIn

The ExoDx Prostate Test was evaluated and its performance characteristics determined by Exosome Diagnostics, Inc. Exosome Diagnostics is certified under the Clinical Laboratory Improvement Amendments (CLIA) Act of 1988 as qualified to perform high complexity clinical testing. CLIA number: 22D2093470. Exosome Diagnostics and ExoDx are registered trademarks of Exosome Diagnostics, Inc.

© 2025 ExoDx

Bottom footer navigation

Privacy Policy